Jorge L Alio1,2, Alejandra E Rodriguez3, Pablo De Arriba1, Sandra Gisbert3, Ahmed A Abdelghany1,4. 1. 1 Research, Development and Innovation Department, VISSUM, Alicante, Spain. 2. 3 Faculty of Medicine, Miguel Hernandez University, Alicante, Spain. 3. 2 Department of Cornea and Refractive Surgery, VISSUM, Alicante, Spain. 4. 4 Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
Abstract
PURPOSE: To assess the effectiveness of autologous platelet-rich plasma for the treatment of dormant corneal ulcers secondary to corneal surgery and unresponsive to conventional treatment. SETTING: VISSUM, Ophthalmology Institute of Alicante, Alicante, Spain. DESIGN: Prospective nonrandomized, observational consecutive study. METHODS: A total of 44 eyes of 28 patients with dormant corneal ulcers secondary to corneal surgery were included in a prospective study and treated with autologous platelet-rich plasma during 6 weeks. Wilcoxon signed-rank test was used to compare the effect of the treatment. RESULTS: In all, 28 patients (65.1%) improved their visual acuity at least one line in Snellen chart, 26 (59.09%) had a decrease in the size of the ulcer or even a total closure, and 40 (90.9%) experienced an improvement in their symptoms. The results are also provided for the four groups of patients (keratoplasty, refractive surgery, cross-linking, and chronic postsurgical corneal edema). CONCLUSION: Platelet-rich plasma eye drops shows to be a good option for the treatment of dormant corneal ulcers secondary to corneal surgery.
PURPOSE: To assess the effectiveness of autologous platelet-rich plasma for the treatment of dormant corneal ulcers secondary to corneal surgery and unresponsive to conventional treatment. SETTING: VISSUM, Ophthalmology Institute of Alicante, Alicante, Spain. DESIGN: Prospective nonrandomized, observational consecutive study. METHODS: A total of 44 eyes of 28 patients with dormant corneal ulcers secondary to corneal surgery were included in a prospective study and treated with autologous platelet-rich plasma during 6 weeks. Wilcoxon signed-rank test was used to compare the effect of the treatment. RESULTS: In all, 28 patients (65.1%) improved their visual acuity at least one line in Snellen chart, 26 (59.09%) had a decrease in the size of the ulcer or even a total closure, and 40 (90.9%) experienced an improvement in their symptoms. The results are also provided for the four groups of patients (keratoplasty, refractive surgery, cross-linking, and chronic postsurgical corneal edema). CONCLUSION: Platelet-rich plasma eye drops shows to be a good option for the treatment of dormant corneal ulcers secondary to corneal surgery.
Authors: Haithem A Farghali; Naglaa A AbdElKader; Huda O AbuBakr; Eman S Ramadan; Marwa S Khattab; Noha Y Salem; Ibrahim A Emam Journal: Front Vet Sci Date: 2021-03-18
Authors: Min He; Xuewen Guo; Tao Li; Xiaoyan Jiang; Yan Chen; Yi Yuan; Bing Chen; Gangyi Yang; Yahan Fan; Ziwen Liang; David G Armstrong; Wuquan Deng Journal: Cell Transplant Date: 2020 Jan-Dec Impact factor: 4.064